BioSpace News Archive

Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, and Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, announced that they have entered into license and inventory purchase agreements for ABO-202, an adeno-associated virus gene therapy for CLN1 disease.

Brain Scientific Inc., a neurology-focused medical device and software company, announced an expansion of their facilities via a headquarter relocation to Bohemia, New York in central Long Island.

Next Generation Material Infused with Proprietary ProBalance Technology™ to Help Maintain Ocular Surface Homeostasis and Help Reduce Contact Lens Dryness, Which Affects More Than Half of Lens Wearers in the United States

Alkermes plc announced the publication of results from the phase 3 ENLIGHTEN-2 clinical trial of ALKS 3831 in the peer-reviewed publication, American Journal of Psychiatry.

Nemaura Medical Inc. provided a business update and on August 14, 2020 released financial results for the quarter ended June 30, 2020.

Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) for Samsung Biologics to produce commercial-scale hRS7, the antibody used in Trodelvy (sacituzumab govitecan-hziy), at its manufacturing facilities in Incheon, South Korea.

Three clinical trial sites activated in Poland, with patient screening initiated Follows activation of six clinical sites in the U.S. and dosing of first three patients Topline data expected in Q1 2021

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”), a clinical stage pharmaceutical development company, is pleased to announce that Christopher J. Moreau, CEO of Algernon, will be providing an update on its two clinical trial programs on a BioPub webcast Wednesday August 19, 2020 hosted by Dr. KSS at noon EDT. The Company invites interested shareholders, investors, member

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, issued a newsletter to update its shareholders from Executive Director and Chief Executive Officer Marc Voigt, which is available below, and a formatted version is available on the Company’s website ( click here ). Dear shareholders, I hope that this newsletter finds

Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced a collaboration with Magle Chemoswed, a Malmö, Sweden-based contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis.